These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

176 related articles for article (PubMed ID: 34167407)

  • 1. Duvelisib as bridge to allotransplantation in refractory peripheral T-cell lymphoma with T-follicular helper phenotype: case report.
    Lolli G; Casadei B; Pellegrini C; Argnani L; Cocito F; Zinzani PL
    Tumori; 2021 Dec; 107(6):NP105-NP107. PubMed ID: 34167407
    [TBL] [Abstract][Full Text] [Related]  

  • 2. DYNAMO: A Phase II Study of Duvelisib (IPI-145) in Patients With Refractory Indolent Non-Hodgkin Lymphoma.
    Flinn IW; Miller CB; Ardeshna KM; Tetreault S; Assouline SE; Mayer J; Merli M; Lunin SD; Pettitt AR; Nagy Z; Tournilhac O; Abou-Nassar KE; Crump M; Jacobsen ED; de Vos S; Kelly VM; Shi W; Steelman L; Le N; Weaver DT; Lustgarten S; Wagner-Johnston ND; Zinzani PL
    J Clin Oncol; 2019 Apr; 37(11):912-922. PubMed ID: 30742566
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Relapsed refractory nodal peripheral T-cell lymphoma with follicular helper T-cell phenotype was initially resistant to pralatrexate and confirmed to be unresponsive to subsequent forodesine, but responded to re-instituted pralatrexate.
    Sekiguchi Y; Wakabayashi M; Takizawa H; Iizuka H; Sakajiri S; Sugimoto K; Inano T; Fukuda Y; Hamano Y; Tomita S; Izumi H; Okubo M; Nakamura N; Sawada T; Komatsu N; Noguchi M
    J Clin Exp Hematop; 2020; 60(1):26-28. PubMed ID: 32224563
    [No Abstract]   [Full Text] [Related]  

  • 4. Duvelisib plus romidepsin in relapsed/refractory T cell lymphomas: a phase 1b/2a trial.
    Horwitz SM; Nirmal AJ; Rahman J; Xu R; Drill E; Galasso N; Ganesan N; Davey T; Hancock H; Perez L; Maccaro C; Bahgat A; Marzouk E; Cathcart E; Moskowitz A; Noy A; Kumar A; Jacobsen E; Fisher DC; Mehta-Shah N; Kim YH; Khodadoust M; Kotlov N; Nikitina A; Kudryashova O; Zubareva V; Zornikova K; Shin N; Sorokina M; Degryse S; Postovalova E; Bagaev A; Hosszu K; McAvoy D; Boelens JJ; Wu W; Ciantra Z; Appelt JW; Trevisani C; Amaka S; Weinstock DM; Vardhana SA
    Nat Med; 2024 Sep; 30(9):2517-2527. PubMed ID: 38886623
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A phase II study of cyclophosphamide, etoposide, vincristine and prednisone (CEOP) Alternating with Pralatrexate (P) as front line therapy for patients with peripheral T-cell lymphoma (PTCL): final results from the T- cell consortium trial.
    Advani RH; Ansell SM; Lechowicz MJ; Beaven AW; Loberiza F; Carson KR; Evens AM; Foss F; Horwitz S; Pro B; Pinter-Brown LC; Smith SM; Shustov AR; Savage KJ; Vose JM
    Br J Haematol; 2016 Feb; 172(4):535-44. PubMed ID: 26627450
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Activity of the PI3K-δ,γ inhibitor duvelisib in a phase 1 trial and preclinical models of T-cell lymphoma.
    Horwitz SM; Koch R; Porcu P; Oki Y; Moskowitz A; Perez M; Myskowski P; Officer A; Jaffe JD; Morrow SN; Allen K; Douglas M; Stern H; Sweeney J; Kelly P; Kelly V; Aster JC; Weaver D; Foss FM; Weinstock DM
    Blood; 2018 Feb; 131(8):888-898. PubMed ID: 29233821
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Efficacy and Safety of Duvelisib Following Disease Progression on Ofatumumab in Patients with Relapsed/Refractory CLL or SLL in the DUO Crossover Extension Study.
    Davids MS; Kuss BJ; Hillmen P; Montillo M; Moreno C; Essell J; Lamanna N; Nagy Z; Tam CS; Stilgenbauer S; Ghia P; Delgado J; Lustgarten S; Weaver DT; Youssoufian H; Jäger U
    Clin Cancer Res; 2020 May; 26(9):2096-2103. PubMed ID: 31964785
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Combination trial of duvelisib (IPI-145) with rituximab or bendamustine/rituximab in patients with non-Hodgkin lymphoma or chronic lymphocytic leukemia.
    Flinn IW; Cherry MA; Maris MB; Matous JV; Berdeja JG; Patel M
    Am J Hematol; 2019 Dec; 94(12):1325-1334. PubMed ID: 31490009
    [TBL] [Abstract][Full Text] [Related]  

  • 9. First-line therapy of peripheral T-cell lymphoma: extension and long-term follow-up of a study investigating the role of autologous stem cell transplantation.
    Wilhelm M; Smetak M; Reimer P; Geissinger E; Ruediger T; Metzner B; Schmitz N; Engert A; Schaefer-Eckart K; Birkmann J
    Blood Cancer J; 2016 Jul; 6(7):e452. PubMed ID: 27471868
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Real-world data on prognostic factors and treatment in peripheral T-cell lymphomas: a study from the Swedish Lymphoma Registry.
    Ellin F; Landström J; Jerkeman M; Relander T
    Blood; 2014 Sep; 124(10):1570-7. PubMed ID: 25006130
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Romidepsin-induced durable remission for relapsed nodal peripheral T-cell lymphoma with T follicular helper phenotype after allogeneic hematopoietic cell transplantation.
    Tao K; Inamoto Y; Furukawa H; Hosoba R; Takeda W; Maeshima A; Aoki J; Ito A; Tanaka T; Kim SW; Makita S; Fukuhara S; Kogure Y; Kataoka K; Izutsu K; Fukuda T
    Int J Hematol; 2023 Aug; 118(2):292-298. PubMed ID: 36807258
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Up-front autologous stem-cell transplantation in peripheral T-cell lymphoma: NLG-T-01.
    d'Amore F; Relander T; Lauritzsen GF; Jantunen E; Hagberg H; Anderson H; Holte H; Österborg A; Merup M; Brown P; Kuittinen O; Erlanson M; Østenstad B; Fagerli UM; Gadeberg OV; Sundström C; Delabie J; Ralfkiaer E; Vornanen M; Toldbod HE
    J Clin Oncol; 2012 Sep; 30(25):3093-9. PubMed ID: 22851556
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Combination of ibrutinib with rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone (R-CHOP) for treatment-naive patients with CD20-positive B-cell non-Hodgkin lymphoma: a non-randomised, phase 1b study.
    Younes A; Thieblemont C; Morschhauser F; Flinn I; Friedberg JW; Amorim S; Hivert B; Westin J; Vermeulen J; Bandyopadhyay N; de Vries R; Balasubramanian S; Hellemans P; Smit JW; Fourneau N; Oki Y
    Lancet Oncol; 2014 Aug; 15(9):1019-26. PubMed ID: 25042202
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A T cell inflammatory phenotype is associated with autoimmune toxicity of the PI3K inhibitor duvelisib in chronic lymphocytic leukemia.
    Gadi D; Griffith A; Tyekucheva S; Wang Z; Rai V; Vartanov A; Thrash E; Fernandes SM; Lehmberg TZ; Lee B; Martindale SP; Machado JH; Odejide O; Armand P; Fisher DC; Arnason J; Davids MS; Lederer JA; Brown JR
    Leukemia; 2022 Mar; 36(3):723-732. PubMed ID: 34743191
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A phase II study of a modified hyper-CVAD frontline therapy for patients with adverse risk diffuse large B-cell and peripheral T-cell non-Hodgkin lymphoma.
    Hapgood G; Stone JM; Zannino D; George A; Marlton P; Prince HM; Hui CH; Prosser I; Lewis ID; Bradstock K; Seymour JF;
    Leuk Lymphoma; 2019 Apr; 60(4):904-911. PubMed ID: 30547695
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Durable clinical remission induced by romidepsin for chemotherapy-refractory peripheral T-cell lymphoma with central nervous system involvement.
    Chan KL; van der Weyden C; Khoo C; Lade S; Blombery P; Westerman D; Khot A; Melo B; Johnstone RW; Prince HM; Dickinson M
    Leuk Lymphoma; 2017 Apr; 58(4):996-998. PubMed ID: 27558082
    [No Abstract]   [Full Text] [Related]  

  • 17. Intensive chemotherapy (high-dose CHOP/ESHAP regimen) followed by autologous stem-cell transplantation in previously untreated patients with peripheral T-cell lymphoma.
    Mercadal S; Briones J; Xicoy B; Pedro C; Escoda L; Estany C; Camós M; Colomo L; Espinosa I; Martínez S; Ribera JM; Martino R; Gutiérrez-García G; Montserrat E; López-Guillermo A;
    Ann Oncol; 2008 May; 19(5):958-63. PubMed ID: 18303032
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Rituximab: a review of its use in non-Hodgkin's lymphoma and chronic lymphocytic leukaemia.
    Plosker GL; Figgitt DP
    Drugs; 2003; 63(8):803-43. PubMed ID: 12662126
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Comparison of CHOP with THP-COP for peripheral T-cell lymphoma-not otherwise specified and angioimmunoblastic T-cell lymphoma: a retrospective analysis using data from the population-based Osaka Cancer Registry.
    Kida S; Fuji S; Morishima T; Nakata K; Miyashiro I; Ishikawa J
    Int J Hematol; 2021 Aug; 114(2):246-251. PubMed ID: 33864237
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Frontline Management of Nodal Peripheral T-Cell Lymphomas.
    Ngu HS; Savage KJ
    Am Soc Clin Oncol Educ Book; 2023 May; 43():e390334. PubMed ID: 37262395
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.